Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway - Episode 5

Clinical Experience with Capivasertib

, ,

Panelists discuss their clinical experiences with capivasertib, focusing on patient tolerability and the management of adverse effects associated with this targeted therapy.

EP. 1: Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer
EP. 2: First-Line Treatment Strategies for HR+/HER2- Advanced Breast Cancer
EP. 3: Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer
EP. 4: Overview of the CAPItello-291 Trial
Now Viewing
EP. 5: Clinical Experience with Capivasertib
EP. 6: Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy
EP. 7: Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia
EP. 8: Best Practices in Managing Patients on Capivasertib

Video content above is prompted by the following:

  1. Can you share your clinical experience with capivasertib and your patient’s tolerability?

Related Content:

Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway
Best Practices in Managing Patients on Capivasertib
Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia
Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy